Lilly’s CVOT Success With Trulicity Causes Bullish Outlook For Diabetes Franchise
Executive Summary
Lilly reported strong sales growth for many of its recently launched products, but news of the potentially differentiating REWIND cardiovascular outcomes trial data dominated the pharma’s third quarter earnings call.
You may also be interested in...
Lilly Aims For Earlier Treatment With Novel Diabetes Drugs
Lilly outlined its tirzepatide-led pipeline of incretin agonists and highlighted its once-weekly basal insulin during a post-ADA event. The company hopes to grow the GLP-1 market overall rather than shift patients from Trulicity.
Q2 Review: Big Pharmas Weigh In On M&A, Pricing Reform
As earnings season reaches its peak, Merck, Lilly, Gilead, Amgen and Sanofi release their second quarter results. Business development remains a dominant theme.
Lilly's Trulicity Shows Unique Cardiovascular Outcomes Benefit, Albeit A Modest One
At the ADA annual meeting, Lilly reported positive results from REWIND, a cardiovascular outcomes trial studying the GLP-1 agonist Trulicity in a broad population of patients with and without established CV disease.